Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2013-07-09 Merger & Acquisition
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
424B5
Merger & Acquisition Classification · 95% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(5) related to an exchange offer by Novavax, Inc. to acquire Isconova AB. It includes extensive information about the terms of the exchange offer, risk factors, financial statements, management discussion and analysis, legal matters, and regulatory considerations. The document is not a simple announcement but a comprehensive offering document used in a merger/acquisition context. The presence of terms like 'Exchange Offer', 'acquisition', 'prospectus', and detailed financial and legal disclosures indicates this is related to M&A activity. Therefore, the document fits best under the 'Merger & Acquisition' category (Code: MA).
2013-07-09 English
Regulatory Filings 2013
Regulatory Filings
2013-07-09 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 8, 2013. It announces the filing of a press release regarding the approval and registration of a Swedish prospectus related to a public tender offer to acquire shares of Isconova AB. The document explicitly states it is a current report and includes a press release as an exhibit. There is no detailed financial data or comprehensive report content; rather, it is an announcement of an event and related filings. The document is under 5,000 characters and serves as a notification of an event rather than a full report or detailed financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2013-07-08 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text mentions a press release about the Swedish Financial Supervisory Authority approving a prospectus related to a public tender offer for Isconova AB shares. It also references a Registration Statement on Form S-4 filed with the SEC, which is related to merger or acquisition activities. The document does not contain financial statements or detailed financial analysis but rather announces an event related to a merger/takeover offer. The presence of Rule 425 communications and the focus on a tender offer strongly indicate this is related to merger and acquisition activity. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length is under 5,000 characters and contains substantive event information, not just a report publication announcement or regulatory filing. Confidence is high due to clear references to merger-related filings and tender offer communications.
2013-07-08 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions an "Other Events" section where the company announces a press release about its RSV vaccine candidate's safety and immunogenicity in elderly subjects. There are no financial statements or detailed financial data included, only a reference to a press release filed as an exhibit. The document length is 2528 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2013-07-05 English
FORM 4/A SUBMISSION
Director's Dealing
2013-07-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.